Dyadic International Regains Nasdaq Compliance
Dyadic International Inc DYAI
$1.05
▼ -1.87%
($-0.02)
🗓️ Earnings Next Week
Open
$1.08
Prev Close
$1.07
Day Range
$1.04 – $1.15
52W Range
$0.65 – $1.60
Market Cap
$38.26M
Beta
1.05
EPS (TTM)
$-0.23
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2004-11-05 |
| Shares Out. | 36,440,000 |
| Website | dyadic.com/ ↗ |
| Phone | 15617438333 |
| Employees | 5 |
| Revenue | $1.1M |
| Gross Profit | $319,116 |
| Net Income | -$2.0M |
| Total Assets | $7.8M |
| Total Liabilities | $8.2M |
| Equity | -$407,732 |
About Dyadic International Inc
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
Dyadic International Inc is a publicly traded company under the ticker symbol DYAI on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-07-01)